Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Aug 3;12:74. doi: 10.1186/1477-7827-12-74

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Wu et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

The percentages of Th17 and Treg cells in peripheral blood mononuclear cells and the Th17/Treg ratio varied with immunotherapy. The percentage of Th17 and Treg cells in peripheral blood mononuclear cells were detected by flow cytometry in the total patient population before and after immunotherapy, respectively. (a) The percentage of Th17 cells in peripheral blood mononuclear cells significantly decreased after immunotherapy (P < 0.01, paired t-test). Bar represents the CD4⁺/IL-17A⁺ cell frequency and values of the means ± S.E. The percentage of Treg cells in peripheral blood mononuclear cells significantly increased after immunotherapy (P < 0.01, paired t-test). Bar represents the frequency of CD4⁺/CD25bright/Foxp3⁺ cells and the means ± S.E. are shown. (b) The Th17/Treg ratio in peripheral blood mononuclear cells significantly decreased after immunotherapy (P < 0.01, paired t-test). Bar represent Th17/Treg ratio in total patients before and after immunotherapy and values of means ± S.E. Representative CD4+/IL-17A + flow cytometry plots in patients are shown before (c) and after (d) immunology. Representative CD4+/CD25bright/Foxp3+ flow cytometry plots in patients are shown before (e) and after (f) immunology.